银杏达莫配合依达拉奉治疗急性脑梗死的应激指标和神经功能变化研究
|
摘要
目的探讨银杏达莫配合依达拉奉治疗急性脑梗死的应激指标和神经功能变化。方法方便选取该院2016年1月—2018年1月收治的90例急性脑梗死患者,根据不同治疗方法分为两组,对照组(n=45)给予依达拉奉治疗,观察组(n=45)在对照组基础上接受银杏达莫治疗,对比两组患者血清应激指标和神经递质指标以及治疗前后神经功能缺损程度和临床疗效。结果观察组IL-6、IL-10、CRP、AOPP、GSH-Px、ox-LDL、MDA、SOD分别为(72.73±3.90)pg/mL、(22.24±1.51)μg/L、(9.29±0.44)mg/L、(76.23±2.63)μmol/L、(40.29±5.17)mg/m L、(86.91±4.15)U/m L、(3.19±0.45)nmol/mL、(163.65±12.04)U/mL,明显优于对照组(135.74±7.10)pg/mL、(40.07±1.67)μg/L、(15.58±1.13)mg/L、(93.84±3.05)μmol/L、(31.76±4.08)mg/mL、(94.49±5.04)U/mL、(5.55±0.31)nmol/mL、(126.23±10.68)U/mL,差异有统计学意义(t=12.179 2、13.035 3、14.795 6、9.332 4、8.688 3、7.788 4、18.971 7、15.597 0,P<0.05)。观察组NSE、Glu、NAA、VAP、NGF、NTF、GABA、NPY分别为(12.24±1.51)μg/L、(72.73±2.90)μmol/L、(430.29±16.44)mmol/L、(8.23±1.63)ng/L、(90.29±2.17)pg/m L、(5.91±0.65)ng/mL、(9.19±0.75)μmol/L、(171.63±5.04)μg/L,明显优于对照组(20.07±1.67)μg/L、(85.74±4.10)μmol/L、(376.58±13.13)mmol/L、(13.64±1.27)ng/L、(61.76±2.08)pg/mL、(3.49±0.44)ng/mL、(6.55±0.61)μmol/L、(184.55±5.68)μg/L,差异有统计学意义(t=13.329 6、7.378 4、7.124 6、7.563 0、6.670 3、10.682 2、8.318 8、11.413 4,P<0.05)。治疗后观察组NIHSS评分(12.24±1.51)分明显低于对照组(19.57±1.67)分,差异有统计学意义(t=8.466 4,P<0.05)。两组患者临床疗效对比95.56%vs82.22%差异有统计学意义(χ~2=9.009 8,P<0.05)。结论银杏达莫配合依达拉奉治疗急性脑梗死可改善改善神经功能,因此值得临床推广。
Objective To investigate the stress and neurological changes of Yinxingdamo combined with edaravone in the treatment of acute cerebral infarction. Methods Convenient select ninety patients with acute cerebral infarction admitted to our hospital(January 2016 to January 2018) were divided into two groups according to different treatment methods. The control group(n=45) was treated with edaravone, and the observation group( n=45) was treated on the basis of the control group with Yinxingdamo, and the serum stress index and neurotransmitter index of the two groups were compared with the degree of neurological deficit and clinical efficacy before and after treatment. Results The IL-6, IL-10, CRP, AOPP, GSHPx, ox-LDL, MDA and SOD in the observation group were(72.73 ±3.90)pg/mL,(22.24 ±1.51)μg/L and(9.29 ±0.44)mg/L,(76.23±2.63)μmol/L,(40.29±5.17)mg/mL,(86.91±4.15)U/mL,(3.19±0.45)nmol/mL,(163.65±12.04)U/mL, significantly better than the control group(135.74±7.10)pg/mL,(40.07±1.67)μg/L,(15.58±1.13)mg/L,(93.84±3.05)μmol/L,(31.76±4.08)mg/mL,(94.49±5.04)U/mL,(5.55±0.31)nmol/mL, and(126.23±10.68)U/mL, the difference was statistically significant(t=12.179 2,13.035 3, 14.795 6, 9.332 4, 8.688 3, 7.788 4, 18.971 7, 15.597 0, P<0.05). The NSE, Glu, NAA, VAP, NGF, NTF, GABA,and NPY of the observation group were(12.24±1.51)μg/L,(72.73±2.90)μmol/L,(430.29±16.44)mmol/L, and(8.23±1.63)ng/L,(90.29 ±2.17)pg/mL,(5.91 ±0.65)ng/mL,(9.19 ±0.75)μmol/L,(171.63 ±5.04)μg/L, significantly better than the control group(20.07±1.67) μg/L,(85.74±4.10)μmol/L,(376.58 ±13.13)mmol/L,(13.64 ±1.27)ng/L,(61.76 ±2.08)pg/mL,(3.49 ±0.44)ng/mL,(6.55±0.61) μmol/L and(184.55±5.68)μg/L, the difference was statistically significant(t=13.329 6, 7.378 4, 7.124 6, 7.563 0,6.670 3, 10.682 2, 8.318 8, 11.443 4, P<0.05). After treatment, the NIHSS score of the observation group was(12.24±1.51)points, which was significantly lower than that of the control group(19.57±1.67)points. The difference was statistically significant(t=8.466 4, P<0.05). The clinical efficacy of the two groups was significantly different from 95.56% vs 82.22%,which was statistically significant(χ~2=9.009 8, P<0.05). Conclusion Yinxingdamo combined with edaravone can improve the improvement of neurological function in the treatment of acute cerebral infarction, so it is worthy of clinical promotion.
Objective To investigate the stress and neurological changes of Yinxingdamo combined with edaravone in the treatment of acute cerebral infarction. Methods Convenient select ninety patients with acute cerebral infarction admitted to our hospital(January 2016 to January 2018) were divided into two groups according to different treatment methods. The control group(n=45) was treated with edaravone, and the observation group( n=45) was treated on the basis of the control group with Yinxingdamo, and the serum stress index and neurotransmitter index of the two groups were compared with the degree of neurological deficit and clinical efficacy before and after treatment. Results The IL-6, IL-10, CRP, AOPP, GSHPx, ox-LDL, MDA and SOD in the observation group were(72.73 ±3.90)pg/mL,(22.24 ±1.51)μg/L and(9.29 ±0.44)mg/L,(76.23±2.63)μmol/L,(40.29±5.17)mg/mL,(86.91±4.15)U/mL,(3.19±0.45)nmol/mL,(163.65±12.04)U/mL, significantly better than the control group(135.74±7.10)pg/mL,(40.07±1.67)μg/L,(15.58±1.13)mg/L,(93.84±3.05)μmol/L,(31.76±4.08)mg/mL,(94.49±5.04)U/mL,(5.55±0.31)nmol/mL, and(126.23±10.68)U/mL, the difference was statistically significant(t=12.179 2,13.035 3, 14.795 6, 9.332 4, 8.688 3, 7.788 4, 18.971 7, 15.597 0, P<0.05). The NSE, Glu, NAA, VAP, NGF, NTF, GABA,and NPY of the observation group were(12.24±1.51)μg/L,(72.73±2.90)μmol/L,(430.29±16.44)mmol/L, and(8.23±1.63)ng/L,(90.29 ±2.17)pg/mL,(5.91 ±0.65)ng/mL,(9.19 ±0.75)μmol/L,(171.63 ±5.04)μg/L, significantly better than the control group(20.07±1.67) μg/L,(85.74±4.10)μmol/L,(376.58 ±13.13)mmol/L,(13.64 ±1.27)ng/L,(61.76 ±2.08)pg/mL,(3.49 ±0.44)ng/mL,(6.55±0.61) μmol/L and(184.55±5.68)μg/L, the difference was statistically significant(t=13.329 6, 7.378 4, 7.124 6, 7.563 0,6.670 3, 10.682 2, 8.318 8, 11.443 4, P<0.05). After treatment, the NIHSS score of the observation group was(12.24±1.51)points, which was significantly lower than that of the control group(19.57±1.67)points. The difference was statistically significant(t=8.466 4, P<0.05). The clinical efficacy of the two groups was significantly different from 95.56% vs 82.22%,which was statistically significant(χ~2=9.009 8, P<0.05). Conclusion Yinxingdamo combined with edaravone can improve the improvement of neurological function in the treatment of acute cerebral infarction, so it is worthy of clinical promotion.
引文
[1]杨成.银杏达莫联合依达拉奉治疗急性脑梗死的临床疗效观察[J].实用心脑肺血管病杂志,2016,24(4):97-99.
[2]李志峰.依达拉奉与银杏达莫对2型糖尿病并发急性脑梗死的治疗效果[J].深圳中西医结合杂志,2018,28(15):50-52.
[3]任俊龙.观察银杏达莫联合依达拉奉治疗老年脑梗死患者的临床效果[J].中国医药指南,2018,16(12):110.
[4]叶超雄,周敏华,何剑锋.补阳还五汤加减佐治气虚血瘀型脑卒中疗效及成本分析[J].光明中医,2018,33(4):493-496.
[5]李向彧.依达拉奉联合银杏达莫辅助治疗急性脑梗死患者疗效观察[J].山西医药杂志,2018,47(3):309-311.
[6]张惠卿,张晓敏,董喜英.依达拉奉联合银杏达莫治疗急性脑梗死的临床疗效[J].临床合理用药杂志,2017,10(21):49-50.
[7]高跃强.银杏达莫联合依达拉奉治疗急性脑梗死的临床疗效及其对患者炎症因子的影响[J].神经损伤与功能重建,2017,12(1):93-94.
[8]夏克志.浅析银杏达莫联合依达拉奉治疗急性脑梗死的临床疗效及安全性[J].中国现代药物应用,2016,10(20):18-19.
[9]林鹏,高伟,丘贺,等.依达拉奉联合银杏达莫治疗2型糖尿病合并急性脑梗塞的临床效果分析[J].现代生物医学进展,2016,16(29):5677-5680.
[10]严烨,冷狂风,陈文丽.依达拉奉联合银杏达莫对缺血性脑卒中患者血清白细胞介素6和肿瘤坏死因子α水平的影响[J].中国医院用药评价与分析,2016,16(9):1169-1171.
[11]王世君,曾兆云,徐青青,等.天丹通络胶囊联合银杏达莫和依达拉奉治疗急性脑梗死的临床研究[J].现代药物与临床,2016,31(9):1342-1346.
[12]郑宋元.依达拉奉联合银杏达莫治疗急性脑梗死的疗效观察[J].现代诊断与治疗,2016,27(17):3191-3193.
[13]牛强.依达拉奉联合银杏达莫治疗脑梗死的临床疗效[J].中国实用神经疾病杂志,2016,19(8):11-13.
[2]李志峰.依达拉奉与银杏达莫对2型糖尿病并发急性脑梗死的治疗效果[J].深圳中西医结合杂志,2018,28(15):50-52.
[3]任俊龙.观察银杏达莫联合依达拉奉治疗老年脑梗死患者的临床效果[J].中国医药指南,2018,16(12):110.
[4]叶超雄,周敏华,何剑锋.补阳还五汤加减佐治气虚血瘀型脑卒中疗效及成本分析[J].光明中医,2018,33(4):493-496.
[5]李向彧.依达拉奉联合银杏达莫辅助治疗急性脑梗死患者疗效观察[J].山西医药杂志,2018,47(3):309-311.
[6]张惠卿,张晓敏,董喜英.依达拉奉联合银杏达莫治疗急性脑梗死的临床疗效[J].临床合理用药杂志,2017,10(21):49-50.
[7]高跃强.银杏达莫联合依达拉奉治疗急性脑梗死的临床疗效及其对患者炎症因子的影响[J].神经损伤与功能重建,2017,12(1):93-94.
[8]夏克志.浅析银杏达莫联合依达拉奉治疗急性脑梗死的临床疗效及安全性[J].中国现代药物应用,2016,10(20):18-19.
[9]林鹏,高伟,丘贺,等.依达拉奉联合银杏达莫治疗2型糖尿病合并急性脑梗塞的临床效果分析[J].现代生物医学进展,2016,16(29):5677-5680.
[10]严烨,冷狂风,陈文丽.依达拉奉联合银杏达莫对缺血性脑卒中患者血清白细胞介素6和肿瘤坏死因子α水平的影响[J].中国医院用药评价与分析,2016,16(9):1169-1171.
[11]王世君,曾兆云,徐青青,等.天丹通络胶囊联合银杏达莫和依达拉奉治疗急性脑梗死的临床研究[J].现代药物与临床,2016,31(9):1342-1346.
[12]郑宋元.依达拉奉联合银杏达莫治疗急性脑梗死的疗效观察[J].现代诊断与治疗,2016,27(17):3191-3193.
[13]牛强.依达拉奉联合银杏达莫治疗脑梗死的临床疗效[J].中国实用神经疾病杂志,2016,19(8):11-13.